Overcoming toxicities when combining PI3K inhibitors with other treatments

Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor to be used in lymphoma, which had remarkable responses on B-cell lymphomas as a single-agent. Nathan Fowler, MD at the University of... Author: VJHemOnc Added: 11/17/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts